文献速递神经免疫

基于神经丝轻链z评分变化优化复发型多发性硬化治疗监测

Refining Treatment Monitoring in Patients With Relapsing Multiple Sclerosis Based on Changes on Neurofilament Light Chain Z-Scores.
PubMed 文献 · Neurology · 2026-08-20

这项前瞻性真实世界队列研究在西班牙加泰罗尼亚多发性硬化中心纳入329例启动疾病修饰治疗的复发型多发性硬化患者,评估治疗1年后血清神经丝轻链z评分变化与后续疾病活动的关联。结果显示z评分未下降与第2年疾病活动风险升高相关,且可为现有治疗反应评分系统提供补充信息。

要点

  • 治疗1年后sNfL z评分未下降与后续疾病活动风险升高相关。
  • 该关联在初治患者和已达NEDA-3的患者中同样存在。
  • ΔzNfL可为临床和MRI监测提供补充信息,但不宜单独使用。

核心结论

  • 治疗1年后zNfL未下降与后续疾病活动相关,即使在其他方面评估稳定的患者中亦然。
  • ΔzNfL可为基于临床和MRI的监测提供补充信息,支持其辅助而非独立角色。

研究设计与样本

  • 前瞻性真实世界队列研究,在加泰罗尼亚多发性硬化中心开展。
  • 纳入329例启动疾病修饰治疗的成人复发型多发性硬化患者,共启动352次治疗。
  • 主要暴露为治疗1年时sNfL z评分变化(ΔzNfL=zNfLY1−zNfL基线),采用数据衍生阈值(ΔzNfL≥0和<0.5分下降)分析。

主要发现

  • 1年时平均(SD)ΔzNfL为−0.62(1.2),单克隆抗体治疗和初治患者下降更明显。
  • zNfL未下降(ΔzNfL≥0)与第2年疾病活动风险升高相关(OR 3.07,95%CI 1.47-6.39,P=0.003)。
  • 初治患者中OR为14.04(95%CI 2.47-79.93,P=0.003),1年时达NEDA-3者中OR为4.54(95%CI 1.26-16.30,P=0.02)。
  • 将ΔzNfL加入治疗反应评分系统后,尽管评分良好,仍与第2年疾病活动持续相关(如RS:OR 2.26,95%CI 1.12-4.59,P=0.024)。

关键数值与推荐

  • ΔzNfL≥0定义为zNfL未下降,<0.5分下降亦显示类似关联。
  • 主要结局为第1至2年间的疾病活动(EDA-Y2)。
  • 治疗反应评分系统包括Rio、改良Rio和MAGNIMS。

临床怎么用

  • 可考虑在治疗1年时检测sNfL z评分变化,辅助识别传统评估认为稳定但仍有后续疾病活动风险的患者。
  • ΔzNfL结果应结合临床和MRI评估及治疗反应评分系统综合解读,不单独用于治疗决策。

局限性

  • 随访数据不完整,仅182例有完整的第2年疾病活动数据。
  • ΔzNfL的区分能力有限,支持其辅助而非独立作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Serum neurofilament light chain (sNfL) reflects inflammatory axonal damage in relapsing multiple sclerosis (RMS). Longitudinal sNfL dynamics may aid treatment response assessment, although data on expected changes under disease-modifying treatments remain limited, particularly in real-world practice. This study evaluated whether on-treatment changes in sNfL were associated with subsequent evidence of disease activity (EDA) and whether they provided complementary information to established treatment response scoring systems (TRSS). METHODS: This prospective, real-world cohort study was conducted at the Multiple Sclerosis Center of Catalonia (Cemcat). Adult RMS patients initiating disease-modifying treatments (DMTs) with serum samples at treatment initiation (baseline) and after 1 year (Y1) were included. The primary exposure was change in sNfL z-scores (ΔzNfL = zNfLY1 - zNfL-baseline) analyzed using data-derived thresholds (ΔzNfL ≥0 and <0.5-point reduction). At Y1, Expanded Disability Status Scale progression, clinical/radiologic activity, and TRSS (Rio [RS], modified Rio [mRS], and MAGNIMS) were assessed. The primary outcome was EDA between years 1 and 2 (EDA-Y2). Multivariable logistic regression models evaluated associations between ΔzNfL and EDA-Y2, as well as the added value of ΔzNfL across TRSS strata. RESULTS: A total of 329 patients (66.3% female; median age 39 years) initiated 352 DMTs; 342 remained on treatment for ≥1 year and 182 had complete EDA-Y2 data. Mean (SD) ΔzNfL at Y1 was -0.62 (1.2), with greater reductions in monoclonal antibody-treated and treatment-naïve patients. Lack of zNfL reduction over the first year (ΔzNfL ≥0) was associated with higher odds of EDA-Y2 in the overall cohort (OR [95% CI], p: 3.07 [1.47-6.39], 0.003), in treatment-naïve cases (14.04 [2.47-79.93], 0.003), and in those achieving No Evidence of Disease Activity (NEDA-3) at Y1 (4.54 [1.26-16.30], 0.02). Similar associations were observed for <0.5-point reductions. Adding ΔzNfL to TRSS showed persistent associations with EDA-Y2 despite otherwise favorable scores [e.g., RS: 2.26 (1.12-4.59), 0.024]. DISCUSSION: Failure to reduce zNfL levels after 1 year of treatment was associated with subsequent disease activity, even in patients otherwise considered stable, providing complementary information to clinical and MRI-based monitoring. Limitations include incomplete follow-up and the modest discriminative performance of ΔzNfL, supporting a complementary rather than stand-alone role for zNfL dynamics.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Fernández V, Pappolla A, Carbonell-Mirabent P, et al. Refining Treatment Monitoring in Patients With Relapsing Multiple Sclerosis Based on Changes on Neurofilament Light Chain Z-Scores. Neurology. 2026. PMID: 42623577. doi:10.1212/WNL.0000000000218451

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。